Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort studyMaría Salgado, Judith Dalmau, Manuel Jurado et al.|The Lancet HIV|2024Cited by 25
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimensJoaquín Burgos, Jorge Palacio, Sergio Moreno‐Fornés et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 22
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, Estebán Martínez, José L Blanco et al.|The Lancet HIV|2025Cited by 22
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched studyDaniel K. Nomah, Maribel Tamayo, Juliana Reyes‐Urueña et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 20
Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic IslandsAndreu Bruguera, Eva Castañer González, Daniel K. Nomah et al.|International Journal of Epidemiology|2023Cited by 14